Results 1 to 10 of about 3,654 (190)

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior ...
Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Kyung Min Kwon, Vithika Suri, Peiwen Wu, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Jeong Won Jang, Soo Hyun Yang, Seung Woon Paik, Hyung Joon Kim, Jung Hyun Kwon, Neung Hwa Park, Ju Hyun Kim, In Hee Kim, Sang Hoon Ahn, Young-Suk Lim   +24 more
doaj   +2 more sources

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort [PDF]

Scientific Reports
Simplified (“minimal monitoring”) pathways can expand access to direct-acting antivirals (DAAs) by reducing visit burden. In Japan, where hepatitis C virus (HCV) patients are among the oldest worldwide, whether DAA regimens can be delivered safely and ...
Goki Suda, Masaru Baba, Yoshiya Yamamoto, Sonoe Yoshida, Tetsuhito Muranaka, Takashi Meguro, Katsumi Terashita, Jun Ito, Tomoe Kobayashi, Takaaki Izumi, Tomofumi Takagi, Shunichi Hosoda, Ren Yamada, Qingjie Fu, Zijian Yang, Daisuke Yokoyama, Takatsugu Tanaka, Akimitsu Meno, Naohiro Yasuura, Takashi Kitagataya, Masatsugu Ohara, Naoki Kawagishi, Masato Nakai, Takuya Sho, Koji Ogawa, Naoya Sakamoto   +25 more
doaj   +2 more sources

Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study [PDF]

Viruses
Background: The advent of direct-acting antivirals (DAAs) has marked a significant milestone in the therapeutic landscape of hepatitis C, greatly improving treatment efficacy.
Jae Hyun Yoon, Chang Hun Lee, Hoon Gil Jo, Ju-Yeon Cho, Jin Dong Kim, Jin Won Kim, Ga Ram You, Sung Bum Cho, Sung Kyu Choi   +8 more
doaj   +2 more sources

Hepatitis C Virus (HCV) Recurrence and Death After Viral Clearance in an HCV-Viremic Donor to HCV-Negative Kidney Recipient [PDF]

Kidney Medicine
Current direct-acting antiviral (DAA) regimens have achieved nearly universal viral eradication in hepatitis C virus (HCV) nucleic acid test (NAT)-positive donor to HCV-negative recipient (HCV NAT+/–) transplantation.
Shengliang He, Tomohiro Tanaka, Sung-Hoon Kim, David Thomsen, Daniel A. Katz, Christie P. Thomas, Prerna Rastogi, Hassan Aziz, Alan I. Reed   +8 more
doaj   +2 more sources

Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis

Frontiers in Gastroenterology
IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (
Huichun Xing
exaly   +3 more sources

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis [PDF]

Clinical and Molecular Hepatology, 2021
Background/Aims Direct‐acting antivirals (DAAs) have been approved for hepatitis C virus (HCV) treatment in patients with end-stage renal disease (ESRD) on hemodialysis.
Po-Yao Hsu, Yu-Ju Wei, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Cheng-Ting Hsu, Tyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Szu-Chia Chen, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Jer-Ming Chang, Shang-Jyh Hwang, Wan-Long Chuang, Chung-Feng Huang, Yi-Wen Chiu, Ming-Lung Yu   +23 more
doaj   +1 more source

SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

Pakistan Armed Forces Medical Journal, 2021
Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study.
Arif Qayyum Khan, Hala Mansoor, Samina Fida, Saba Saif, Javed Iqbal, Muhammad Siddique   +5 more
doaj   +1 more source

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

Journal of Education, Health and Sport, 2023
Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules.
Kamila Abram, Patryk Banaś, Justyna Adamus, Jakub Rafał Pierzchała, Katarzyna Bednarz, Natalia Sobańska, Aleksandra Paulina Banasiak, Rafał Teichman, Jakub Kasprowicz, Michał Hyjek   +9 more
doaj   +1 more source

Molecular docking analysis of peptide-based antiviral agents against SARS-CoV-2 main protease: an approach towards drug repurposing

Exploration of Medicine, 2023
Aim: Utilizing the therapeutic potentials of previously approved medications against a new target or pharmacological response is known as drug repurposing.
Abhishek Chaurasiya, Abhimannu Shome, Pooja A. Chawla   +2 more
doaj   +1 more source

In-Vitro and In-Vivo Evaluation of Velpatasvir- Loaded Mesoporous Silica Scaffolds. A Prospective Carrier for Drug Bioavailability Enhancement

Pharmaceutics, 2020
The limited aqueous solubility of many active pharmaceutical ingredients (APIs) is responsible for their poor performance and low drug levels in blood and at target sites. Various approaches have been adopted to tackle this issue.
Yasir Mehmood, Ikram Ullah Khan, Yasser Shahzad, Rizwan Ullah Khan, Muhammad Shahid Iqbal, Haseeb Ahmad Khan, Ikrima Khalid, Abid Mehmood Yousaf, Syed Haroon Khalid, Sajid Asghar, Muhammad Asif, Talib Hussain, Shefaat Ullah Shah   +12 more
doaj   +1 more source